α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.

Dis Markers 2011 ;30(5):221-7

Laboratoire Hématopoïèse Leucémique et Cibles Thérapeutiques, Université Victor Segalen Bordeaux, France.

Objective: Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imatinib is our point of interest.

Methods: Gene expression profiling microarray was carried out on secondary imatinib resistant patients. Longitudinal studies were performed on imatinib treated responder/resistant patients. Then, Q-RT/PCR studies were realized on patients prior imatinib initiation.

Results: For imatinib responder patients, we observed a strong and lasting decrease of α-defensin 1-3 and α-defensin 4 expression. For relapse patients, we observed a dramatic increase of α-defensin 1-3 and α-defensin 4 expression before BCR-ABL transcript increase. Moreover, before imatinib initiation, α-defensin 1-3 and α-defensin 4 expression was significantly lower in the resistant group than in the responder group.

Conclusion: The variation of expression of α-defensin 1-3 and α-defensin 4 in peripheral blood is associated with imatinib resistance and may reflect an adequate immune control of the disease. Monitoring of α-defensin 1-3 and α-defensin 4 could be helpful to predict the patients who are not going to respond to the treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3233/DMA-2011-0777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825081PMC
October 2011
13 Reads

Publication Analysis

Top Keywords

1-3 α-defensin
24
α-defensin 1-3
24
α-defensin
12
α-defensin expression
12
imatinib
9
patients
8
patients observed
8
imatinib resistance
8
cml patients
8
1-3
5
expression
5
initiationresults imatinib
4
observed strong
4
responder patients
4
imatinib responder
4
imatinib initiationresults
4
decrease α-defensin
4
relapse patients
4
observed dramatic
4
expression relapse
4

Similar Publications